Virtu Financial’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Virtu Financial’s Portfolio DRMAW Stock Details DRMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+11,029	New	+$156	﹤0.01%	1756
2025 Q3	–	Sell	-10,856	Closed	–	–	1598
2025 Q2	$0	Buy	+10,856	New	+$201	﹤0.01%	1606
2022 Q2	–	Sell	-18,171	Closed	-$3K	–	1689
2022 Q1	$3K	Buy	+18,171	New	+$5.14K	﹤0.01%	1407

Other funds holding DRMAW

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Virtu Financial's DRMAW Position: Q2 2026 in Review

Virtu Financial opened a new position in Dermata Therapeutics Warrant (DRMAW) in Q2 2026: 11,029 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1756 among its holdings. This is a return to the name: Virtu Financial previously reported a position in DRMAW as recently as Q2 2025.

Virtu Financial first reported a position in DRMAW in Q1 2022 and has held it in 3 quarters since. The position peaked at $3K in Q1 2022. 3 funds tracked by Wall St. Rank hold DRMAW as of Q2 2026.

Virtu Financial held 11,029 shares of Dermata Therapeutics Warrant worth $0 as of Q2 2026.
Dermata Therapeutics Warrant was a new Virtu Financial position in Q2 2026.
Dermata Therapeutics Warrant made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1756 holding.
Virtu Financial first reported a position in Dermata Therapeutics Warrant in Q1 2022 and has held it in 3 quarters since.
Virtu Financial's Dermata Therapeutics Warrant position peaked at $3K in Q1 2022.
3 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.